Drugs / Xilonix plus Onivyde and 5FU
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03207724 | Oct 2017 → Nov 2019 | hypoproteinemia, hypercatabolic, pancreatic ductal adenocarcinoma | Andrew Hendifar, MD | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Xilonix plus Onivyde and 5FU | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03207724 ↗ |
| Known as | Nal-Iri | “In this phase I dose-escalation trial, we assess the maximum tolerated dose (MTD) of Bermekimab in combination with Nanoliposomal Irinotecan (Nal-Iri) and...” PMID 36056179 ↗ Sep 2022 |